Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Praxis Precision Medicines in a report issued on Tuesday, November 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($13.45) for the year, up from their prior estimate of ($14.09). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($14.03) per share.
A number of other equities analysts also recently issued reports on the company. Raymond James Financial reissued a "strong-buy" rating and set a $945.00 price target on shares of Praxis Precision Medicines in a research report on Monday, August 17th. Wedbush upped their price target on shares of Praxis Precision Medicines from $188.00 to $189.00 and gave the company an "underperform" rating in a research note on Tuesday. Weiss Ratings restated a "sell (d-)" rating on shares of Praxis Precision Medicines in a research note on Monday, August 24th. Wall Street Zen downgraded Praxis Precision Medicines from a "hold" rating to a "sell" rating in a research note on Saturday, October 17th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $575.00 price objective (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $631.68.
Read Our Latest Analysis on PRAX
Praxis Precision Medicines Price Performance
Shares of PRAX stock opened at $346.21 on Thursday. The company has a market capitalization of $9.67 billion, a P/E ratio of -27.05 and a beta of 2.85. The company's 50-day simple moving average is $291.10 and its two-hundred day simple moving average is $314.16. Praxis Precision Medicines has a one year low of $160.11 and a one year high of $392.70.
Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($3.23) EPS for the quarter, beating the consensus estimate of ($3.54) by $0.31.
Institutional Trading of Praxis Precision Medicines
A number of hedge funds have recently bought and sold shares of PRAX. GW&K Investment Management LLC acquired a new stake in shares of Praxis Precision Medicines in the 3rd quarter worth $61,488,000. Ieq Capital LLC increased its position in shares of Praxis Precision Medicines by 11.5% during the third quarter. Ieq Capital LLC now owns 909 shares of the company's stock valued at $265,000 after acquiring an additional 94 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Praxis Precision Medicines by 2.6% in the 3rd quarter. Voya Investment Management LLC now owns 125,359 shares of the company's stock valued at $36,508,000 after acquiring an additional 3,132 shares during the period. Public Sector Pension Investment Board purchased a new stake in shares of Praxis Precision Medicines in the 3rd quarter valued at approximately $6,990,000. Finally, Royce & Associates LP lifted its holdings in shares of Praxis Precision Medicines by 93.7% in the 3rd quarter. Royce & Associates LP now owns 12,675 shares of the company's stock worth $3,691,000 after acquiring an additional 6,131 shares during the last quarter. Institutional investors and hedge funds own 67.84% of the company's stock.
Praxis Precision Medicines News Summary
Here's some of the latest news about PRAX:
- Positive Sentiment: BTIG and RBC Capital issued “Buy” ratings. RBC also raised its price target to $478 from $462 and maintained an “Outperform” rating, signaling confidence in potential appreciation. BTIG Buy rating RBC Capital Buy rating
- Neutral Sentiment: Praxis presented at the Guggenheim Healthcare Innovation Conference; the provided coverage is a transcript and does not identify a specific new catalyst.
- Negative Sentiment: Wells Fargo cut its price target to $343 from $362 and kept an “Equal Weight” rating. Wedbush raised its target only slightly, to $189 from $188, but retained an “Underperform” rating; both targets are below the share price cited in the reports.
Praxis Precision Medicines Company Profile
(
Get Free Report)
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.